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Using genetically matched azole-susceptible (AS) and azole-resistant (AR) clinical isolates of
Candida albicans, we recently demonstrated that CDR1 overexpression in AR isolates is due to
its enhanced transcriptional activation and mRNA stability. This study examines the molecular
mechanisms underlying enhanced CDR1 mRNA stability in AR isolates. Mapping of the
39 untranslated region (39 UTR) of CDR1 revealed that it was rich in adenylate/uridylate (AU)
elements, possessed heterogeneous polyadenylation sites, and had putative consensus
sequences for RNA-binding proteins. Swapping of heterologous and chimeric lacZ–CDR1
39 UTR transcriptional reporter fusion constructs did not alter the reporter activity in AS and AR
isolates, indicating that cis-acting sequences within the CDR1 39 UTR itself are not sufficient to
confer the observed differential mRNA decay. Interestingly, the poly(A) tail of the CDR1 mRNA of
AR isolates was ~35–50% hyperadenylated as compared with AS isolates. C. albicans poly(A)
polymerase (PAP1), responsible for mRNA adenylation, resides on chromosome 5 in close
proximity to the mating type-like (MTL) locus. Two different PAP1 alleles, PAP1-a/PAP1-a, were
recovered from AS (MTL-a/MTL-a), while a single type of PAP1 allele (PAP1-a) was recovered
from AR isolates (MTL-a/MTL-a). Among the heterozygous deletions of PAP1-a (Dpap1-a/PAP1-a)
and PAP1-a (PAP1-a/Dpap1-a), only the former led to relatively enhanced drug resistance, to
polyadenylation and to transcript stability of CDR1 in the AS isolate. This suggests a dominant
negative role of PAP1-a in CDR1 transcript polyadenylation and stability. Taken together, our study
provides the first evidence, to our knowledge, that loss of heterozygosity at the PAP1 locus is linked
to hyperadenylation and subsequent increased stability of CDR1 transcripts, thus contributing to
enhanced drug resistance.
INTRODUCTION
One of the major mechanisms of the multidrug resistance
(MDR) phenotype in azole-resistant (AR) Candida albicans
clinical isolates is characterized by the overexpression of
genes encoding ATP binding cassette (ABC) multidrug
transporters such as CDR1/CDR2 (Akins, 2005; Prasad
et al., 1995; Sanglard et al., 1995, 1997; Sanglard & Odds,
2002; White, 1997; White et al., 1998), or major facilitator
superfamily (MFS) pumps such as CaMDR1 (Wirsching
et al., 2000). Once acquired, MDR is a stable phenotype
that is maintained in AR clinical isolates even in the
absence of selection pressure by the drugs (White, 1997;
White et al., 1997). This implies that some genetic
alterations take place in the azole-susceptible (AS) isolates,
resulting in constitutive overexpression of the drug efflux
pump-encoding genes in AR isolates. Therefore, cellular
elements contributing to the overexpression of MDR genes
Abbreviations: AR, azole-resistant; AS, azole-susceptible; LOH, loss of
heterozygosity; MDR, multidrug resistance; NouR, nourseothricin-resist-
ant; PAT, polyadenylation test; RACE, rapid amplification of cDNA ends;
39 UTR, 39 untranslated region.
A set of supplementary results, two supplementary figures and three
supplementary tables, with references, are available with the online
version of this paper. The supplementary results describe how 39 UTR of
CDR1 mRNA forms altered secondary structures. The supplementary
figures show the predicted secondary structure of CDR1 39 UTR and
the results of a lacZ mRNA decay assay. The supplementary tables list
primers, plasmids and strains used in this study.
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in AR isolates are very critical in designing strategies for
therapeutic interventions.
Transcriptional regulation of CDR1 has been extensively
studied by several groups. It has been shown that CDR1
harbours various consensus (Sp1, AP-1, Y-box) sequences
as well as specific basal (BRE), negative (NRE) and drug/
steroid response elements (DRE and SRE) in the 59
flanking region (De Micheli et al., 2002; Gaur et al.,
2004; Karnani et al., 2004; Puri et al., 1999). Trans-acting
factors regulating CDR1 have also been identified. For
example, non dityrosine 80 (CaNDT80), a homologue of a
meiosis specific transcription factor (TF) of Saccharomyces
cerevisiae, has been identified as a potential activator of
CDR1 (Chen et al., 2004). Coste et al. (2004) identified a
TF, transcriptional activator of cDR genes (TAC1), that
binds to the DRE in both the CDR1 and the CDR2
promoters. Interestingly, a TF belonging to the zinc cluster
family, fluconazole resistance 1 (FCR1) (Talibi &
Raymond, 1999), as well as the global repressor thymidine
uptake 1 (Tup1), acts as a negative regulator of CDR1
expression (Yang et al., 2006). Recent genome-wide
location profiling (ChIP-chip) results show that another
TF of the zinc cluster family, uptake control 2 (Upc2),
which regulates ERG genes, also targets CDR1 (Znaidi et
al., 2008). The efforts of several groups have also led to the
identification of various cis-acting elements such as the
H2O2 responsive element (HRE) and the benomyl
responsive element (BRE) in the MDR1 promoter region,
mediating its upregulation in AS isolates and its constitu-
tive activation in AR isolates (Rognon et al., 2006).
Recently a zinc cluster TF, designated multidrug resistance
regulator 1 (MRR1), has been identified, which is linked to
the activation of MDR1 expression. Inactivation of MRR1
abolishes the resistance of Mdr1p-overexpressing strains
(Morschha¨user et al., 2007).
It is thus apparent that transcriptional regulation plays an
important role in the mechanism underlying the over-
expression of MDR genes; however, the relevance of the
post-transcriptional events associated with it is poorly
understood. By employing two pairs of matched C. albicans
clinical isolates in which azole resistance developed due to
the overexpression of CDR1 during prolonged azole
therapy, we have recently shown that the high mRNA
levels in AR isolates are predominantly contributed by both
enhanced transcriptional activation and mRNA stability
(Manoharlal et al., 2008). In this study, we further
dissected the molecular basis of CDR1 mRNA turnover
in matched clinical isolates. For this, we have identified and
characterized the complete 39 end of the CDR1 mRNA by
the 39-rapid amplification of cDNA ends (39-RACE)-PCR
method in these matched isolates. Our observations with
chimeric lacZ–CDR1 39 UTR transcriptional reporter
fusion transformants ruled out the participation of the 39
UTR in transcriptional as well as post-transcriptional
control of CDR1. However, there was an increase in
poly(A) tail length, which coincided with the enhanced
CDR1 mRNA stability in AR isolates. Poly(A) tail synthesis
in C. albicans is catalysed by the nuclear poly(A)
polymerase that resides within the mating type-like
(MTL) locus on chromosome 5.
The MTL loci of C. albicans span approximately 9 kb and
contain S. cerevisiae mating-type homologues MAT-a1,
MAT-a1 and MAT-a2 (Hull & Johnson, 1999), as well as
genes unique to fungal mating loci, including OBP (an
oxysterol-binding protein), PAP1 [a poly(A) polymerase 1]
and PIK1 (a phosphoinositol kinase). A copy of each of
these three genes is present in both the MTL-a and the
MTL-a locus. The MTL genes have no significant
homology to each other. The a and a versions of PAP1,
PIK1 and OBP have approximately 60% homology to each
other. Most wild-type C. albicans strains are diploid and
have both the MTL-a and MTL-a loci (Magee & Magee,
2000). However, our analysis of PAP1 allelic status revealed
that MTL heterozygosity (MTL-a/MTL-a) and homozyg-
osity (MTL-a/MTL-a) are linked to the acquisition of
PAP1 heterozygosity (PAP1-a/PAP1-a) and homozygosity
(PAP1-a/PAP1-a) in AS and AR isolates, respectively. We
also show that heterozygous disruption of PAP1-a
conferred relatively enhanced drug resistance, hyperadeny-
lation and increased stability of CDR1 transcripts in AS
isolates. However, heterozygous disruption of PAP1-a in
AS and AR affected neither the drug resistance nor the
polyadenylation or stability of CDR1 transcripts. Therefore,
our results provide evidence that loss of heterozygosity
(LOH) at the PAP1 locus is associated with the hyper-
adenylation and increased stability of CDR1 transcripts and
that this helps the development of drug resistance in AR
isolates.
METHODS
Materials. Media chemicals were obtained from HiMedia. Luria–
Bertani broth and agar media were purchased from Difco, BD
Biosciences. Restriction endonucleases, DNA-modifying enzymes,
Taq DNA polymerase and ultrapure deoxyribonucleotides (dATP,
dGTP, dCTP and dTTP) for PCR were purchased from New England
Biolabs. Moloney murine leukaemia virus (M-MuLV) reverse
transcriptase, IPTG, X-Gal, T7 and Sp6 promoter primers were
obtained from MBI Fermentas. Radiolabelled [a-32P]dATP was
obtained from Bhabha Atomic Research Center (BARC), India. The
Megaprime DNA labelling system was procured from Amersham
Pharmacia Biotech. The pGEMT-Easy vector system II used for T/A
DNA cloning purposes was purchased from Promega. Nourseothricin
was obtained from Werner Bioagents. Gel elution and PCR
purification kits were obtained from Qiagen. Oligonucleotides used
were commercially synthesized by Sigma–Aldrich (Supplementary
Table S1). All molecular biology grade chemicals used in this study
were obtained from Sigma Chemical.
Bacterial and yeast strains and growth media. Escherichia coli
DH-5a was used as a host for plasmid construction and propagation.
Plasmids and C. albicans strains used in this study are listed in
Supplementary Tables S2 and S3. E. coli was cultured in Luria–Bertani
broth media to which ampicillin was added (100 mg ml21). C.
albicans strains were maintained on yeast extract peptone dextrose
(YEPD) media. For agar plates, 2.5% (w/v) Bacto Agar was added to
the medium. All strains were stored as frozen stocks with 15% (v/v)
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glycerol at 280 uC. Before each experiment, cells were freshly revived
on YEPD plates from this stock.
3§-Rapid amplification of cDNA ends (3§-RACE). The nucleotide
sequence of the oligonucleotide primers used for the reverse
transcription-39-RACE-nested PCR were selected based on the
published sequences of CDR1 (GenBank accession no. X77589)
(Prasad et al., 1995). Total RNA isolated from each isolate using the
TRIzol reagent (as per the manufacturer’s specifications) was
enriched with poly(A)+ (polyadenylated) mRNA using the Oligotex
mRNA Mini kit protocol (Qiagen) and used subsequently for
performing the reverse transcription-39-RACE reaction as described
elsewhere (Gerads & Ernst, 1998). For a typical 39-RACE reaction,
cDNA synthesized from ~0.1 mg poly(A)+ RNA was placed in a
0.5 ml reaction tube with 1 mM oligo(dT)18 anchor primer stock, and
the volume was adjusted to 11 ml with diethylpyrocarbonate (DEPC)-
treated water (Fig. 1a, step 1). The mixture was incubated for 10 min
at 70 uC and chilled on ice for 1 min, after which the remainder of the
reaction mixture was added from a master mix to the reaction tube in
order for each reaction to contain a 1 mM concentration of each of
dATP, dCTP, dGTP and dTTP, and 40 U RNase inhibitor (MBI,
Fermentas) in a buffer consisting of 50 mM Tris/HCl (pH 8.3),
50 mM KCl, 4 mM MgCl2 and 10 mM DTT. After brief mixing, the
reaction was incubated for 10 min at 37 uC followed by addition of
Fig. 1. Determination of termination sites of CDR1 mRNA. (a) The 39-RACE strategy employed for the detection of CDR1 39
UTR length is detailed in Methods. Briefly, cDNA synthesized from poly(A)+-enriched mRNA samples from clinical C. albicans
isolates was PCR-amplified using CDR1-specific forward and reverse anchor primers. Following electrophoresis, the amplified
PCR products were visualized by staining with ethidium bromide (indicated by a long thick arrow), cloned and sequenced. To
confirm the RT-PCR specificity, another round of 39 UTR-specific nested PCR amplification of CDR1 of each isolate was
performed. Following electrophoresis, the amplified PCR products were further visualized by staining with ethidium bromide
(indicated by a short thick arrow), cloned and sequenced. The locations of DNA size markers (bp) are marked on the left-hand
side of the gel. C. albicans isolates are labelled above the gels. (b) Schematic representations of the mapped 39 UTRs of
CDR1. The open box and wavy line represent the CDR1-coding and poly(A) tail-harbouring 39 end regions respectively, while
thick straight lines with numbers on top indicate the mapped CDR1 39 UTR length of each isolate.
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40 U M-MuLV reverse transcriptase (MBI, Fermentas). Finally, the
reaction was incubated at 37 uC for 60 min and then stopped by
heating at 70 uC for 10 min followed by chilling on ice for 1 min. The
synthesized cDNA was used for amplification of the CDR1 mRNA-
specific 39 end of each isolate (Fig. 1a, step 2), using the
corresponding appropriate dilution of cDNA as template (determined
empirically for CDR1 to give a product in the linear range, generally
1 : 4) and 1 mM of each CDR1-specific forward primer CT-CDR1-F-
RM (corresponding to positions 4271–4293 in the CDR1 genomic
sequence) and reverse PCR anchor primer as described in
Supplementary Table S1. PCR parameters were initial denaturation
of 95 uC for 5 min, followed by 35 cycles of denaturation at 95 uC for
30 s, annealing at 55 uC for 40 s, elongation at 72 uC for 40 s and
final extension at 72 uC for 10 min. As a positive control, CDR1-
specific forward primer CT-CDR1-F-RM and reverse primer CT-
CDR1-R-RM (corresponding to positions 4475–4503 in the CDR1
genomic sequence) were also used (data not shown). The negative
control (without reverse transcriptase) established that the PCR
products generated in the RT-PCR were not due to genomic DNA
contamination (data not shown). The RT-PCR product of each
isolate was electrophoresed on a 1.2% agarose gel in 16 TAE. The
gel-purified 39-RACE product (Qiagen PCR Cleanup kit) of each
isolate was cloned directly in the pGEMT-Easy vector using a T/A
cloning kit (Promega) as per the manufacturer’s recommendations
and sequenced (Fig. 1a, step 3). The corresponding clone of each
isolate was sequenced and subsequently used as template for a second
nested PCR amplification of CDR1 (Fig. 1a, step 4) with forward and
reverse primers (UTR-F-PacI and UTR-R-MluI, Supplementary Table
S1) specific to each isolate. PCR parameters were: initial denaturation
at 95 uC, followed by 30 cycles of denaturation at 95 uC for 30 s,
annealing at 55 uC for 30 s, elongation at 72 uC for 30 s and final
extension at 72 uC for 10 min. The resulting PCR-amplified
fragments (now exactly specific to mapped 39 UTR CDR1 of each
isolate) were purified (Qiagen PCR Cleanup kit) and further
subcloned in pGEMT-Easy (Fig. 1a, step 5a), generating CDR1 39
UTR-specific clones of each isolate, as described in Supplementary
Table S2. All the cloned PCR-amplified products were confirmed by
appropriate restriction digestion analysis and sequenced further to
determine the exact and precise length of the CDR1 39 UTR (Fig. 1a,
step 5b).
Custom service nucleotide sequencing. Multiple 39 UTR-specific
clones of each isolate were sequenced directly by extension from both
sense and antisense strands using T7 promoter/T7 promoter primer
and SP6 promoter/SP6 promoter primer (Supplementary Table S1)
by exploiting BigDye Terminator chemistry and an automated DNA
sequencer (ABI Prism 3100). Reproducibility of the sequencing was
confirmed by processing all samples at least twice.
Sequence alignments, in silico analysis and computerized
secondary structure predictions of CDR1 3§ UTR. Multiple
sequence alignment of mapped CDR1 39 UTR for both matched pairs
of isolates was done using the CLUSTAL W (version 1.83) program
(Thompson et al., 1994). In silico analysis of the 39 UTR for prediction
of the putative regulatory site was carried out by the UTRscan
(UTResources) program (Pesole et al., 2002; Pesole & Liuni, 1999).
We used the mfold (version 3.0) algorithm created by Zuker et al.
(1999) for in silico computer predictions of the secondary structure of
the 39 UTR by a minimization of free energy-based method. The
folding temperature was fixed at 37 uC and ionic conditions were 1 M
NaCl without constraints, and no limit in the maximum distance
between paired bases.
Reporter plasmid construction. Plasmid pCPL51 (Manoharlal et
al., 2008), harbouring PCDR1–lacZ, was used for cloning of the
mapped CDR1 39 UTR in transcriptional fusion with a heterologous
lacZ reporter. For this purpose, sequences at the junctions of lacZ–
TACT1 and TACT1–caSAT1 were mutated sequentially by introducing
PacI and MluI sites at these corresponding junctions (lacZ–TACT1 and
TACT1–CaSAT1) using lacZ-F-PacI-RM/lacZ-R-PacI-RM and lacZ-F-
MluI-RM/lacZ-R-MluI-RM primers (Supplementary Table S1) with a
QuikChange site-directed mutagenesis system (Stratagene) to gen-
erate the plasmids pCPL53-RM (with PacI site only) and pCPL54-RM
(with both PacI and MluI sites introduced), respectively. Mapped
CDR1 39 UTR fragments of each isolate were excised from their
corresponding 39 UTR-harbouring pGEMT-Easy vector clones
(Supplementary Table S2) by digestion at PacI and MluI sites (sites
introduced in primers during the synthesis), and further subcloned in
PacI/MluI-digested pCPL54-RM to generate pCPL54-Gu4/Gu5-
39UTR-RM and pCPL54-DSY294/DSY296-39UTR-RM (Supple-
mentary Table S2). All constructs were confirmed by appropriate
restriction digestion analysis. The flanking CDR1 sequences in all
these plasmids served for genomic integration of the PCDR1-lacZ-39
UTR reporter fusion cassettes at the native CDR1 locus, and the
dominant CaSAT1 marker (Reuss et al., 2004) was used to select
nourseothricin-resistant (NouR) transformants.
Yeast transformation. C. albicans was transformed by the standard
electroporation protocol (Reuss et al., 2004). Briefly, 5 ml (~1 mg) of
the specific enzyme-digested and gel-purified linearized DNA
fragments was mixed with 40 ml electrocompetent cells and electro-
porated using a Bio-Rad Genepulser XL (0.2 cm cuvette, 1.5 kV).
Following electroporation, transformants were washed with 1 ml 1 M
sorbitol, resuspended in 1 ml YEPD medium and incubated for 3–4 h
with shaking at 30 uC prior to plating on YEPD plates containing
200 mg nourseothricin ml21 and grown at 30 uC. NouR transformants
were picked after 1 day of growth and restreaked on YEPD plates
containing 100 mg nourseothricin ml21.
b-Galactosidase reporter assay. b-Galactosidase assays were
performed using duplicate samples of cells from three independent
experiments, as described by Uhl & Johnson (2001). b-Galactosidase
activity was determined by the standard equation and expressed in
Miller units (mg protein)21. Miller units are arbitrary units:
b-Galactosidase activity (Miller units)5(A42061000)/(OD6006t6v)
where t is the time of reaction (min) and v is the culture volume (ml).
Polyadenylation test (PAT) analysis of poly(A) tail length. A new
and improved variation of the 39-RACE PAT involving G-tailing of
mRNA was employed to show both the presence of the poly(A) tail
and its length, as described elsewhere (Kusov et al., 2001).
Guanylation of mRNA. The purified poly(A)+-enriched mRNA (as
described above) was used directly for polyguanylation using yeast
poly(A) polymerase (PAP) (catalogue number E74225Y, Amersham
Pharmacia Biotech/US Biochemicals) as per the manufacturer’s
recommendations. To abolish the higher-ordered secondary structure
at the 39 end of the mRNA, samples (0.1 mg) were heated at 65 uC for
5 min and immediately placed on ice. They were incubated for 1 h at
37 uC with 600 U PAP and 0.5 mM GTP in a 25 ml reaction mixture
containing 20 mM Tris/HCl (pH 7.0), 50 mM KCl, 0.7 mM MnCl2,
0.2 mM EDTA, 100 mg BSA ml21 and 10% (v/v) glycerol. An
additional 300 U PAP was further added and incubation was
continued for an additional 1 h. The reaction was terminated by
heat treatment at 65 uC for 10 min, chilled on ice and kept at 280 uC
till further use.
RT-PCR. Polyguanylated mRNA (as described above) was subjected
directly to RT-PCR analysis using hot start conditions (65 uC, 30 s).
The first-strand cDNA synthesis (reverse-transcription, 42 uC for 1 h)
was primed by oligo(dC9T6)-anchor primer (1 mM). The reverse-
transcription reaction was stopped by denaturation at 70 uC for
10 min; the synthesized cDNA product (1 : 4 dilution) was used for
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PCR amplification with 1 mM of each CDR1-specific forward primer
(CT-CDR1-F/UTR-F-PacI) and reverse anchor primer as described in
Supplementary Table S1. PCR parameters were: initial denaturation
of 95 uC for 5 min, followed by 35 cycles of denaturation at 95 uC for
30 s, annealing at 55 uC for 30 s, elongation at 72 uC for 1 min and
final extension at 72 uC for 10 min. The PCR products were gel-
purified and used for cloning into the T/A cloning vector as
recommended by the manufacturer (Promega). Approximately 8–10
random clones from at least three independent RT-PCRs for each
isolate were sequenced.
Construction of gene disruption cassettes. Two different PAP1
disruption cassettes were designed in this study. Two cassettes,C1 and
C2, in plasmids pRM3 and pRM4 were designed using the URA-
blaster system (Fonzi & Irwin, 1993). C1 bears the deletion of a
portion of 602 bp between nucleotides +500 and +1102 with
respect to the first ATG codon of PAP1-a. C2 was designed to delete a
region of 636 bp between nucleotides +750 and +1386 with respect
to the first ATG codon. To construct these two deletion cassettes (C1
and C2), the entire PAP1-a ORF and a portion of the PAP1-a ORF
(corresponding to nucleotides +259 to +1677 with respect to the
first ATG codon) were first amplified from genomic DNA of DSY294
and DSY296, respectively, using the cloning primer pairs PAP-a-F-
BamHI-RM/PAP-a-R-XhoI-RM and PAP-alpha-F-BamHI-RM/PAP-
alpha-R-XhoI-RM, respectively (Supplementary Table S1). The
resulting PCR fragments were cloned into pBluescript-KS(+) to
yield pRM1 and pRM2, respectively (Supplementary Table S2). For
disruption with cassettes C1 and C2, deletions were created from
pRM1 and pRM2 by PCR using deletion primer pairs PAP-a-F-BglII-
RM/PAP-a-R-PstI-RM and PAP-alpha-F-BglII-RM/PAP-alpha-R-
PstI-RM, respectively (Supplementary Table S1). The obtained PCR
fragment was digested with PstI and BglII, and the 3.7 kb PstI/BglII
URA3-blaster fragment from pMB7 (Fonzi & Irwin, 1993) was
inserted to obtain deletion constructs pRM3 and pRM4, respectively
(Supplementary Table S2). The linearized fragments C1 and C2,
obtained by digestion of deletion constructs (pRM3 and pRM4) with
ApaI/SacI, were used for transformation in C. albicans. It is of note
that Dura3 mutants of the clinical isolates DSY294 and DSY296, i.e.
DSY3040 and DSY3041 (Coste et al., 2006), respectively, were used
for PAP1 disruptions and subsequent experiments. After generation
of heterozygous mutants for each allele, the ura3 marker was
regenerated by plating Ura+ colonies on selective medium containing
5-fluoroorotic acid (5-FOA), as described previously (Sanglard et al.,
1996). The verification of heterozygous mutants was performed by
PCR using an internal and an external recombination-specific primer
(results not shown).
Construction of revertant strains. Complementation of hetero-
zygous PAP1 mutants was achieved by expression of PAP1-a and
PAP1-a under the control of their native promoters. PAP1-a and
PAP1-a ORFs with 500 bp of the 59- and 39-flanking regions were
amplified from genomic DNA of DSY294 and DSY296, respectively,
by PCR with primer pairs PAP-aC-F-XhoI-RM/PAP-aC-R-PstI-RM
and PAP-alphaC-F-XhoI-RM/PAP-alphaC-R-PstI-RM, respectively
(Supplementary Table S1). The resulting PCR fragment was digested
with restriction enzymes XhoI and PstI (sites introduced in primers
during the synthesis) and cloned in the same sites of the CIp10 vector
(Murad et al., 2000) to yield pRM5 (harbouring PAP1-a) and pRM6
(harbouring PAP1-a). CIp10-derived plasmids pRM5 and pRM6,
harbouring nourseothricin as selectable marker, were digested with
StuI and used to transform heterozygous PAP1 mutants in which the
ura3marker had been regenerated as described above (Supplementary
Table S3). The NouR transformants were analysed by PCR to confirm
the reintegration of the PAP1 alleles.
Drug susceptibility testing. Drug susceptibility testing was
performed by spotting cells onto solid agar plates containing the
tested drugs (see Fig. 5 for drug concentrations used). Yeast cultures
were grown overnight in YEPD and diluted to a density of 1.56107
cells ml21, and 10-fold serial dilutions were performed to a final
dilution step containing 1.56103 cells ml21. Five microlitres of each
dilution were spotted onto YEPD plates with or without drugs. Plates
were incubated for 48 h at 30 uC.
Thiolutin chase assay. To measure the CDR1 mRNA half-life, a
potent in vivo transcriptional inhibitor of C. albicans, thiolutin, at an
optimized concentration (40 mg) was used as described previously
(Manoharlal et al., 2008). Briefly, 100 ml cells was grown at 30 uC to
OD600 1.0. Aliquots of cells were taken at the indicated times after
transcriptional shutoff by thiolutin. Total RNA was isolated using the
Ambion RiboPure-Yeast RNA isolation kit (catalogue no. 1926) as per
the manufacturer’s instructions. Equal RNA loading was assessed by
staining the agarose gel with ethidium bromide prior to blotting. For
Northern blots, ~25 mg total RNA from the above samples was
hybridized with a single probe derived from CDR1-specific primers
(primer pairs KM1 and KM2, Supplementary Table S1) that was used
throughout this study. Hybridization signal intensity was quantified with
a phosphorimager scanner (FLA-5000, FLA5000 Fuji phosphorimager),
normalized to the band intensity at time t0 and plotted as a line graph.
RESULTS
We have analysed two pairs of matched clinical AS and AR
C. albicans strains isolated from recurrent episodes of
oropharyngeal candidiasis (OPC) in two different human
immunodeficiency virus-positive (HIV+) AIDS patients,
in whom MDR in AR isolates is predominantly linked to
overexpression of CDR1 (Franz et al., 1999; Sanglard et al.,
1995). Our recent study on the molecular characterization
of CDR1 and its products (mRNA/protein) in these clinical
isolates suggested that the MDR phenotype is governed by
enhanced transcription activation and the mRNA stability
of the CDR1 transcript (Manoharlal et al., 2008). In this
study, we have explored the molecular basis of the mRNA
stability of CDR1 in AR isolates.
The 3§ UTR of CDR1 mRNA displays length
heterogeneity
As an initial step to study the post-transcriptional
mechanisms involved in enhanced CDR1 mRNA stability,
transcription termination sites of CDR1 in AS and AR
isolates were determined by the 39-RACE method (Gerads
& Ernst, 1998). For this, RT-PCR products of CDR1 of
each isolate were generated (Fig. 1a, step 1 and 2) using the
CDR1-specific forward primer CT-CDR1-F-RM and
oligo(dT)18AP-RM anchor primer (Supplementary Table
S1), cloned directly into the pGEMT-Easy vector and
sequenced (Fig. 1a, step 3). To further confirm the RT-PCR
specificity of CDR1 (because of close homology of CDR1
with CDR2), a subsequent second round of nested PCR of
corresponding CDR1 39 UTR-harbouring clones (Fig. 1a,
step 3) was performed with CDR1 39 UTR-specific primers
for each isolate (Fig. 1a, step 4) (Supplementary Table S1).
39 UTR products specific to CDR1 for each isolate were
amplified and further subcloned into pGEMT-Easy (Fig.
1a, step 5a). Direct sequencing (Fig. 1a, step 5b) of multiple
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39 UTR-specific clones of AS and AR isolates confirmed
and revealed exact transcription termination sites of CDR1
(data not shown). For the matched isolates Gu4/Gu5 and
DSY294/DSY296, 39 UTR length was mapped to 137/163
bases and 162/137 bases, respectively (positions are relative
to the UAA stop codon) (Fig. 1b).
CDR1 3§ UTR sequences reveal polymorphism and
potential mRNA destabilizing signals
Since differences in sequence at the 39 UTR could be involved
in polyadenylation site selection (Edwalds-Gilbert et al., 1997)
and mRNA stability (Russell et al., 1998), we did a
comparative in silico analysis of mapped 39 UTR fragments
of CDR1 of AS and AR isolates and analysed their relevant
sequence features. 39 UTR sequence alignment of CDR1
revealed polymorphism at positions 27U (insertion), U19C
and C64U (substitution) [Fig. 2a, open box, where the base(s)
before and after the number is the sequence from Gu4 and
Gu5 isolates, respectively] and an additional extended 26 and
25 base AU (adenylate/uridylate)-rich stretch at the 39 end for
only Gu5 (AR) and DSY294 (AS) isolates, respectively
(Fig. 2a). All nucleotide positions are relative to the UAA
translational stop codon (considered as+1).
Fig. 2. Sequence analysis of CDR1 39 UTR. (a) Alignment of CDR1 39 UTRs from the two matched pairs of clinical isolates
obtained using the CLUSTAL W program (Thompson et al., 1994). Conserved residues are indicated by asterisks. Mismatched
residues are represented by open boxes. Gaps (marked with dashes) have been introduced to maximize the alignments.
Continuous and discontinuous underlining denotes the polypyrimidine (Py) and cytoplasmic polyadenylation element (CPE)
tract, respectively. The eukaryotic poly(A) signal is indicated by shaded boxes. Elliptical boxes denote the AU-rich elements
(AAUAAA). Numbers at the right are relative to the UAA translational stop codon (considered as position +1). (b) Schematic
representation of the predicted regulatory motifs in the 39 UTR, indicated by boxes.
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The CDR1 39 UTR is ~78% AU, represents several putative
consensus sequences for cytoplasmic RNA-binding pro-
tein(s) (Fig. 2b), and has perfect AU-rich elements (AURE)
(Fig. 2a, elliptical boxes). The AURE motifs are character-
ized by the presence of the consensus sequence (AUUUA)
and have been reported to be involved in destabilization of
their corresponding mRNAs (Trzaska & Dastych, 2005).
The presence of one perfect (UAGU) and two degenerate
(A/CAUAAA, AAUAAA/U) yeast polyadenylation signals
(Fig. 2a, shaded boxes), suggests that mRNA variants
influence the CDR1 mRNA steady-state levels, as has been
reported for other cells (Edwalds-Gilbert et al., 1997;
Higgins, 1991; Hsu et al., 1990). A poly(U)-rich and a
cytoplasmic polyadenylation element (CPE) tract were also
predicted (Fig. 2a, continuous and discontinuous under-
lining, respectively).
3§ UTR swapping does not affect b-galactosidase
reporter activity
The sequence and structure analyses of the 39 UTR of
CDR1 suggested that the polymorphism (Fig. 2a) as well as
differential secondary structure (Supplementary Fig. S1) of
AS and AR isolates contribute to the observed enhanced
mRNA stability. To obtain direct experimental evidence,
we tested whether the CDR1 39 UTR from AS isolates has
any mRNA destabilizing effect in AR isolates and vice
versa. For this purpose, expression vectors harbouring
PCDR1-lacZ-CDR1 39 UTR chimeric transcriptional
reporter fusions were constructed (Fig. 3a, see Methods).
The linearized transformation cassette of each isolate was
integrated into the native CDR1 genomic locus in
corresponding matched isolates. Single-copy integration
of each construct was confirmed by Southern hybridization
(data not shown). Two representative NouR transformants
of each parental strain were used for further analysis. The
resulting reporter strains were designated Gu4L2-CUN
(PCDR1-lacZ-39UTR
N), Gu4L2-CUS (PCDR1-lacZ-39UTR
S);
Gu5L2-CUN (PCDR1-lacZ-39UTR
N), Gu5L2-CUS (PCDR1-
lacZ-39UTRS); DSY294L2-CUN (PCDR1-lacZ-39UTR
N),
DSY294L2-CUS (PCDR1-lacZ-39UTR
S); and DSY296L2-
CUN (PCDR1-lacZ-39UTR
N) and DSY296L2-CUS (PCDR1-
lacZ-39UTRS). The superscripts ‘N’ and ‘S’ in the
designated constructs stand for native and swapped
CDR1 39 UTR reporter transformants, respectively.
Expression of the lacZ reporter gene in various strains was
qualitatively assessed by comparing the intensity of the blue
colour produced by cells grown on agar plates containing
the indicator dye X-Gal (Fig. 3b), and was quantified by
measuring the b-galactosidase reporter activity in liquid
assays (Fig. 3c). Two observations emerged from these
results. First, the b-galactosidase activity observed in native
as well as swapped 39 UTR transformants of each AR
isolate was always higher than their corresponding AS
reporter transformants (3.22-fold for Gu5L2-CUN versus
Gu4L2-CUN, 2.33-fold for Gu5L2-CUS versus Gu4L2-
CUS; 4.44-fold for DSY296L2-CUN versus DSY294L2-CUN
and 3.86-fold for DSY296L2-CUS versus DSY294L2-CUS).
Second, the reporter activity of the 39 UTR native
transformants of either AS or AR isolates was comparable
with that of their corresponding swapped reporter fusion
transformants (Gu4L2-CUN versus Gu4L2-CUS, Gu5L2-
CUN versus Gu5L2-CUS, DSY294L2-CUN versus
DSY294L2-CUS, and DSY296L2-CUN versus DSY294L2-
CUS). Thus, swapping of the CDR1 39 UTR of AS and AR
isolates did not affect the reporter activity. In another set of
experiments, we observed comparable lacZ transcript half-
lives in native as well as swapped 39UTRs of CDR1 in both AS
and AR isolates (Supplementary Fig. S2). The influence of the
39 UTR of CDR1 was measured by employing a heterologous
lacZ reporter. However, the possibility that the CDR1 39 UTR
might have a cis effect on transcriptional or post-transcrip-
tional control of its transcript cannot be ruled out.
CDR1 mRNA poly(A) tail length is longer in AR
isolates
Since poly(A) tail removal is a critical step in the 39-
exonuclease-mediated mRNA decay pathway (Higgins,
1991; McCarthy, 1998; Ross, 1996), we checked the
polyadenylation status of CDR1 mRNA between AS and
AR isolates. For this, we employed a recently described
PCR-based PAT assay, where the 39 end of the mRNA is
polyguanylated using yeast poly(A) polymerase, as
described earlier (Kusov et al., 2001). With this step, a
poly(A)–oligo(G) junction is generated, which serves as
specific target for the amplification of the 39 end of the
transcriptome with the universal reverse oligo(dC9T6)
anchor primer and a gene-specific forward primer. RT-
PCR products were cloned and sequenced for the accurate
measurement of poly(A) tail length. Chromatogram
analysis of cloned PAT-PCR products of each AS and AR
isolate confirmed precisely that the CDR1 poly(A) tail
length was shorter, with 24±2 A residues in AS isolates, in
contrast to 35±2 A residues in AR isolates (Table 1; a
maximum variation of ±2 bases was observed between
different clones). It should be mentioned that a minimum
of 10 random clones were subjected to sequencing to
determine the precise poly(A) tail length.
Poly(A) polymerase 1 (PAP1) is heterozygous
(PAP1-a/PAP1-a) in AS isolates but homozygous
(PAP1-a/PAP1-a) in AR isolates
In eukaryotes, poly(A) tail synthesis at the 39 end of
mRNAs in the nucleus is catalysed by the canonical poly(A)
polymerase (PAP), which belongs to the DNA polymerase-
like nucleotidyl transferase superfamily (Holm & Sander,
1995). C. albicans poly(A) polymerase (PAP1) is located
within the MTL locus on chromosome 5 (Coste et al.,
2006). To analyse the PAP1 allelic status in AS and AR
isolates, oligonucleotides were designed to specifically
amplify the two PAP1 alleles PAP1-a and PAP1-a
(Supplementary Table S1). For this, multiplex PCR was
performed with genomic DNA of each of the isolates, as
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Fig. 3. Schematic depiction of lacZ reporter fusion integrants and qualitative and quantitative assay of b-galactosidase reporter
activity in AS and AR isolates. (a) Structure of the DNA cassettes used to integrate the PCDR1-lacZ-39UTR
N (native) and PCDR1-
lacZ-39UTRS (swapped) reporter fusions into the CDR1 locus of the clinical C. albicans isolates (centre). The CDR1- and lacZ-
coding regions are represented by white and blue arrows, respectively, the SAT1 marker by a grey arrow, and the 39 UTR of
CDR1 by the filled circle. CDR1 upstream and downstream regions are represented by solid lines; the CDR1 promoter (PCDR1)
is symbolized by the bent arrow. The straight arrow indicates the direction of transcription. The probe used to verify the correct
integration is indicated by a thick line. Only relevant restriction sites are shown. (b) Transformants harbouring the chromosomally
integrated PCDR1-lacZ-39UTR
N (native, left) and PCDR1-lacZ-39UTR
S (swapped, right) constructs and their corresponding
parental strains (without lacZ) were streaked on minimal medium plates containing X-Gal and photographed after 3 days of
growth at 30 6C. The positions of the individual strains on the plates are shown in the scheme (centre). (c) b-Galactosidase
quantitative reporter activities of each transformant were determined as described in Methods. The reported quantities are
mean±SD (indicated by error bars) of three independent experiments with duplicate measurements of two independent clones.
Empty and filled bars indicate PCDR1-lacZ-39UTR
N (native) and PCDR1-lacZ-39UTR
S (swapped) reporter fusion transformants in
both AS and AR backgrounds.
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detailed in Methods. We observed from PCR amplicon
analyses that while PAP1-a and PAP1-a alleles were
generated from both the AS isolates, only the PAP1-a
allele could be recovered from AR isolates (Fig. 4).
PAP1-a disruption decreases drug susceptibilities
of AS isolates
It has been demonstrated earlier that while both the PAP1
alleles (Dpap1-a/PAP1-a and PAP1-a/Dpap1-a) are inde-
pendently functional in heterozygous deletion mutants,
they are collectively essential, since a Dpap1-a/Tet-PAP1-a
conditional mutant is not viable under Tet-repressing
conditions (Jiang et al., 2008). To get an insight into the
functional relevance of the observed PAP1 allelic status in
AS and AR clinical isolates, we used ura32 mutants
DSY3040 (derived from DSY294) and DSY3041 (derived
from DSY296) (Coste et al., 2006). For this, heterozygous
mutants of PAP1-a (Dpap1-a/PAP1-a) and of PAP1-a
(PAP1-a/Dpap1-a) in AS, and a single PAP1-a allele
disruptant (Dpap1-a/PAP1-a) in AR, were constructed, as
detailed in Methods. These heterozygous PAP1 mutants
were tested for their drug susceptibilities, wherein drug
spot assays were performed on YEPD plates containing
fixed drug concentrations (Fig. 5a, b). The heterozygous
PAP1-a mutant (Dpap1-a/PAP1-a) of AS isolates revealed
reduced susceptibility to tested drugs as compared with the
parental strain DSY3040 (Fig. 5a). Notably, the observed
reduced susceptibility of the heterozygous PAP1-a mutant
(Dpap1-a/PAP1-a) of the AS isolate to the tested drugs
could be reversed if complemented with the PAP1-a allele
(Dpap1-a/PAP1-a+PAP1-a). On the other hand, the
heterozygous disruption of PAP1-a and its complementa-
tion in both AS and AR isolates resulted in drug
sensitivities comparable with those of the respective
parental strains, DSY3040 and DSY3041 (Fig. 5a, b).
PAP1-a disruption (Dpap1-a/PAP1-a) results in
hyperadenylation of CDR1 transcripts in AS
isolates
We checked further whether heterozygous disruption of
PAP1-a and PAP1-a in AS and AR isolates could affect the
polyadenylation of CDR1 transcripts. For this, we carried out
PAT analysis (as described inMethods) with the heterozygous
PAP1-a mutant (Dpap1-a/PAP1-a). This analysis revealed
that PAP1-a deletion in DSY3040 (24±2 A residues) leads to
hyperadenylation (35±2 A residues) of CDR1 transcripts
(Table 2). Notably, the complementation of the heterozygous
PAP1-a mutant with PAP1-a (Dpap1-a/PAP1-a+PAP1-a)
restored the polyadenylation status of CDR1 transcripts to
basal level (Table 2). In contrast, the disruption of PAP1-a
(PAP1-a/Dpap1-a) as well as its subsequent complementation
(PAP1-a/Dpap1-a+PAP1-a) in AS did not affect the
polyadenylation of the CDR1 transcript (Table 2). With
regard to the PAP1-a allele in the AR isolate, neither its
heterozygous disruption (Dpap1-a/PAP1-a) nor its comple-
mentation (Dpap1-a/PAP1-a+PAP1-a) influenced the poly-
adenylation status of CDR1 transcripts (Table 2).
PAP1-a disruption results in increased stability of
CDR1 transcripts in AS isolates
Since, in eukaryotes, most mature mRNAs having a poly(A)
tail at their 39 end participate in mRNA stability (Higgins,
1991; McCarthy, 1998; Ross, 1996), we evaluated whether
the observed decrease in drug susceptibility and increase in
polyadenylation of CDR1 transcripts in a heterozygous
PAP1-a mutant (Dpap1-a/PAP1-a) within the AS back-
ground correlates with enhanced stability of its mRNA.
Using a thiolutin chase assay, we revealed increased half-life
of CDR1 transcripts (t1/2 ~120 min) in a Dpap1-a/PAP1-a
mutant (RMY4) in contrast to its parental counterpart,
DSY3040 (t1/2 ~60 min). The increased CDR1 transcript
stability of RMY4 could be reversed to parental levels if
complemented with the PAP1-a allele (Dpap1-a/PAP1-
a+PAP1-a) (Fig. 6a, b). It is of note that the CDR1
mRNA decay rate of the heterozygous PAP1-a mutant
Table 1. Representative CDR1 transcript poly(A) tail lengths
and corresponding transcript half-lives in clinical AS and AR
isolates
Strain CDR1 transcript
poly(A) tail length
CDR1 transcript
half-life* [t1/2 (min)]
Gu4 26±2 ~60
Gu5 35±2 .180
DSY294 24±2 ~60
DSY296 36±2 .180
*The CDR1 transcript half-lives of the mentioned matched pairs of AS
and AR isolates were deduced previously (Manoharlal et al., 2008).
Fig. 4. Analysis of PAP1 allele status in AS and AR isolates. The
PAP1 allelic status of both the matched clinical pairs was analysed
by multiplex PCR using PAP1-a- and PAP1-a-specific primers
(Supplementary Table S1). As a positive control, MTL allele-
specific primers (MTL-a and MTL-a) were used. Lanes: 1, Gu4
(MTL-a/MTL-a); 2, Gu5 (MTL-a/MTL-a); 3, Gu4 (PAP1-a/PAP1-
a); 4, Gu5 (PAP1-a/PAP1-a); 5, DSY294 (MTL-a/MTL-a), 6,
DSY296 (MTL-a/MTL-a); 7, DSY294 (PAP1-a/PAP1-a); 8,
DSY296 (PAP1-a/PAP1-a).
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remained intermediate (t1/2 ~120 min) to that of AS (t1/2
~60 min) and AR isolates (t1/2 ~180 min) (Fig. 6a, b),
indicating that along with PAP1-a, some additional
unknown mechanism(s) also contribute to enhanced
CDR1 transcript stability in AR isolates. Notably, hetero-
zygous PAP1-a mutants of AS (Dpap1-a/PAP1-a) and AR
isolates (Dpap1-a/PAP1-a), and their complemented coun-
terparts, PAP1-a/Dpap1-a+PAP1-a and Dpap1-a/PAP1-
a+PAP1-a, respectively, did not affect the stability of
CDR1 transcripts (Fig. 6a, b).
DISCUSSION
In many AR clinical isolates of C. albicans, a positive
correlation between resistance and CDR1 overexpression
has been reported by several independent research groups
(Franz et al., 1998, 1999; Lopez-Ribot et al., 1998; White,
1997; White et al., 1998). Various other studies have
dissected the cis-acting elements in the CDR1 promoter
region (De Micheli et al., 2002; Gaur et al., 2004; Karnani et
al., 2004; Puri et al.,1999) and identified its transcription
factor(s) (Chen et al., 2004; Coste et al., 2006; Znaidi et al.,
2008), which contribute to its differential mRNA expres-
sion in AS and AR isolates. We have recently observed that
along with increased transcriptional activation, enhanced
mRNA stability can also contribute to the sustained CDR1
overexpression in AR isolates (Manoharlal et al., 2008). In
the present study, we evaluated the cause(s) of the
increased CDR1 mRNA stability in AR isolates.
By employing a 39-RACE method, we mapped and observed
the variation in the length of the 39 UTR of CDR1 in AS and
AR isolates (Fig. 1a, b). Notably, the heterogeneous product
lengths at the 39 ends observed were not specific to AS or AR
isolates, since each isolate exhibited a 39 UTR length for
CDR1 independent of the azole susceptibility as well as of the
level of CDR1 expression. The existence of this heterogeneity
at the 39 end of CDR1 can be explained by the alternative
usage of several polyadenylation signals, as has been well
documented for other unrelated MDR genes (Edwalds-
Gilbert et al., 1997; Hsu et al., 1990). For example, although
evolutionarily quite distant from yeast, mouse mdr1a (Hsu
et al., 1990) and EhPgp5 mRNA of Entamoeba histolytica
trophozoites responsible for the MDR phenotype (Lopez-
Camarillo et al., 2003) also show length variations at their 39
ends, which affects mRNA half-life. Notably, several other
yeast genes also produce multiple transcripts with different
39 ends as a result of a carbon source-regulated choice
between alternative polyadenylation sites (Sparks &
Dieckmann, 1998).
In silico analysis and secondary structure prediction of
mapped CDR1 39 UTR (~78% AU-rich) suggest the
Fig. 5. Drug susceptibility testing of PAP1
mutants and revertant clinical strains. Drug
susceptibility assays were carried out on
YEPD medium containing 2 mg fluconazole
ml”1 (for AS) and 5 mg fluconazole ml”1 (for
AR), 15 mg terbinafine ml”1 and 300 mg
cycloheximide ml”1. Spotting assays were
performed with serial dilutions of overnight
cultures onto YEPD medium containing the
indicated drugs. Plates were incubated for
48 h at 30 6C. Graduation filled bars indicate
10-fold serial dilutions of culture, as described
in Methods. Strains and genotypes: DSY3040,
PAP1-a/PAP1-a; RMY4, Dpap1-a/PAP1-a;
RMY7, Dpap1-a/PAP1-a+pap1-a; RMY5,
PAP1-a/Dpap1-a; RMY10, PAP1-a/Dpap1-
a+PAP1-a; DSY3041, PAP1-a/PAP1-a;
RMY6, Dpap1-a/PAP1-a; RMY12, Dpap1-a/
PAP1-a+PAP1-a.
Table 2. Representative CDR1 transcript poly(A) tail lengths
and corresponding transcript half-lives in PAP1 mutant and
revertant clinical strains
Strains and genotypes: DSY3040, PAP1-a/PAP1-a; RMY4, Dpap1-a/
PAP1-a; RMY7, Dpap1-a/PAP1-a+PAP1-a; RMY5, PAP1-a/Dpap1-a;
RMY10, PAP1-a/Dpap1-a+PAP1-a; DSY3041, PAP1-a/PAP1-a;
RMY6, Dpap1-a/PAP1-a; RMY12, Dpap1-a/PAP1-a+PAP1-a.
Strain CDR1 transcript
poly(A) tail length
CDR1 transcript
half-life [t1/2 (min)]
DSY3040 24±2 ~60
RMY4 35±2 ~120
RMY7 24±2 ~60
RMY5 24±2 ~60
RMY10 24±2 ~60
DSY3041 36±2 ~180
RMY6 36±2 ~180
RMY12 36±2 ~180
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Fig. 6. CDR1 mRNA decay assay. Exponentially growing cultures of C. albicans were incubated with the optimized thiolutin
concentration (40 mg ml”1) to inhibit ongoing in vivo transcription (as described in Methods). Total RNA was isolated at the
times indicated thereafter and fractionated on a 1% (w/v) agarose/2.2 M formaldehyde denaturing gel. (a) The gel was stained
with ethidium bromide before blotting to monitor equal loading of the RNA and subsequently blotted onto a charged nylon
membrane. The blot was hybridized with [a-32P]dATP-labelled CDR1-specific probe. Time points in minutes are indicated
below the equally loaded RNA gel. (b) The hybridization signals were quantified using densitometry scanning in a
phosphorimager scanner. The signal intensity at each time point was normalized to that of time t0 (expressed as a percentage)
and plotted as a line graph. t1/2, half-life. Strains and genotypes: DSY3040, PAP1-a/PAP1-a; RMY4, Dpap1-a/PAP1-a; RMY7,
Dpap1-a/PAP1-a+PAP1-a; RMY5, PAP1-a/Dpap1-a; RMY10, PAP1-a/Dpap1-a+PAP1-a; DSY3041, PAP1-a/PAP1-a;
RMY6, Dpap1-a/PAP1-a; RMY12, Dpap1-a/PAP1-a+PAP1-a.
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existence of various regulatory RNA sequences and
structural motifs in both AS and AR isolates (Fig. 2a, b
and Supplementary Fig. S1). To experimentally test the
proposed mRNA destabilizing activity of these predicted
CDR1 39 UTR regulatory motifs, the reporter activity of
lacZ in transcriptional fusion with the CDR1 39 UTR of
either AS or AR isolates was examined (Fig. 3a).
Interestingly, swapping of the CDR1 39 UTR between AS
and AR had no effect on lacZ reporter activities (Fig. 3b, c)
or on its mRNA half-life (Supplementary Fig. S2),
indirectly indicating that the CDR1 39 UTR is not sufficient
to affect either the transcription or the mRNA stability of
CDR1. Notably, mammalian MDR1 39 UTR (Prokipcak et
al., 1999) and EhPgp5 39 UTR (Lopez-Camarillo et al.,
2003), which also harbour putative regulatory RNA motifs,
do not behave as active destabilizing elements for their
corresponding mRNAs.
The mRNA abundance of a typical gene is affected by a
concerted interplay of key factors such as the activities of
poly(A) polymerase, deadenylases and poly(A)-binding
proteins (Zhao et al., 1999). The pre-mRNAs are
polyadenylated in a reaction involving 39-endonucleolytic
cleavage followed by poly(A) tail synthesis (Zhao et al.,
1999). The poly(A) tail is considered to be a strong
modulator of mRNA stability, and its length is subjected to
cellular control throughout the life span of the mRNA
(Higgins, 1991; McCarthy, 1998; Ross, 1996). It is well
known that longer poly(A) tails provide higher stability to
mRNA and promote a more efficient translation (Higgins,
1991; McCarthy, 1998; Ross, 1996). In our study, PAT
assay revealed that CDR1 mRNA has an ~30–35% longer
poly(A) tail in AR strains than in their respective matched
AS isolates (Table 1), suggesting that polyadenylation and
deadenylation events occur at different rates that could
affect CDR1 mRNA half-life. The relatively longer poly(A)
tail of EhPgp5 mRNA has been shown to be associated with
its enhanced half-life in Entamoeba histolytica trophozoites
grown in the presence of the drug emetine (Lopez-
Camarillo et al., 2003). Interestingly, this increased
poly(A) tail length of EhPgp5 mRNA has been associated
with the Entamoeba histolytica nuclear poly(A) polymerase
(EhPAP) that catalyses the poly(A) tail synthesis of mRNA
in the nucleus (Garcia-Vivas et al., 2005).
C. albicans PAP1, which is responsible for polyadenylation
of mRNA, is located within the MTL locus on chromosome
5, where TAC1 and its linkage with the MTL in
determining TAC1 hyperactivity have been established
(Coste et al., 2006). It has been recently shown that a
hyperactive TAC1 allele is responsible for CDR1 as well as
CDR2 upregulation in isolate DSY296 (Coste et al., 2006).
The existence of an association among MTL, TAC1 and
PAP1 is an exciting possibility that needs to be explored. It
is of note that Sanglard’s group has shown by comparative
genome hybridization (CGH) and single nucleotide
polymorphism (SNP) arrays that LOH of TAC1 in an AR
clinical isolate (DSY296) can occur either by recombina-
tion between portions of chromosome 5 or by chro-
mosome 5 duplication. LOH is not restricted to MTL but
also extends to ~250 kb flanking regions that also comprise
PAP1 alleles within MTL (Coste et al., 2006). Consistent
with published results, we recovered two distinct PAP1
alleles (PAP1-a/PAP1-a) from AS (MTL-a/MTL-a) and a
single type of PAP1 allele (PAP1-a) in matched AR isolates
(MTL-a/MTL-a) (Fig. 4). It is of note that these two
isoforms of C. albicans PAP1, PAP1-a (ORF 19.3197) and
PAP1-a (ORF 19.10713), share only ~70% amino acid
identity (Hull & Johnson, 1999). Earlier evidence of
differential susceptibilities of the two PAP1 isoforms to a
natural product, parnafungin, suggests a difference in their
in vivo activity (Jiang et al., 2008). We established
differences in PAP1-a and PAP1-a activities by construct-
ing heterozygous mutants in both AS and AR backgrounds.
Notably, the heterozygous PAP1-amutant (Dpap1-a/PAP1-
a) displayed enhanced drug resistance as compared with
the AS isolate (Fig. 5a), which could be reversed by
complementing the PAP1-a allele in this heterozygous
mutant (Dpap1-a/PAP1-a+PAP1-a, Fig. 5a). Subsequent
analysis of relative hyperadenylation (Table 2) and
decreased decay rate of CDR1 mRNA (Fig. 6a, b) in this
heterozygous PAP1-a mutant suggests that PAP1-a has a
dominant negative effect on PAP1-a activity. It seems that
PAP1-a disruption in AS isolates leads to de-repression of
PAP1-a activity, thereby leading to hyperadenylation and
increased stability of CDR1 transcripts. This observation is
consistent with the unchanged drug susceptibilities of
heterozygous PAP1-a mutant in both AS (PAP1-a/Dpap1-
a) and AR (Dpap1-a/PAP1-a) isolates (Fig. 5a, b). This was
accompanied by unaltered polyadenylation status (Table 2)
as well as stability of CDR1 transcripts (Fig. 6a, b).
However, it should be noted that in the heterozygous
PAP1-a mutant of AS isolates, although CDR1 transcript
polyadenylation status switches from AS to AR level (24±2
to 35±2 A residues), its mRNA decay rate remains
intermediate (t1/2 ~120 min) to that of AS (t1/2 ~60 min)
and AR isolates (t1/2 ~180 min) (Fig. 6a, b, Table 2). This
implies that along with increased poly(A) tail length, some
additional mechanism(s) also contribute to enhanced
CDR1 transcript stability in AR isolates.
In conclusion, our results provide what we believe to be the
first evidence that LOH at the PAP1 locus contributes to
hyperadenylation and subsequent increased CDR1 tran-
script stability, and ultimately enhanced drug resistance in
AR isolates. We recently observed that all TAC1 target
genes show relatively higher transcriptional rates and
mRNA half-lives in AR isolates (our unpublished observa-
tions). However, whether the observed increase in poly(A)
tail length in AR isolates is specific to CDR1 transcripts
alone or represents a general feature of the mRNA
population of Tac1p targets as well as other transcripts
within the ORFome of C. albicans remains to be
established. Certainly, further characterization of the
functional role of PAP1 should lead to a better under-
standing of mechanisms underlying post-transcriptional
events and should also be useful for the development of
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antifungal strategies that can be exploited to combat MDR
in C. albicans.
ACKNOWLEDGEMENTS
We are grateful to Joachim Morschha¨user, Universita¨t Wu¨rzburg,
Germany, for providing the clinical isolates Gu4/Gu5. We thank
Chinmay K. Mukhopadhyay, Special Centre for Molecular Medicine
(SCMM), Jawaharlal Nehru University, New Delhi, India, for providing
the valuable advice on the PAT assay. Thiolutin (CP-4092) and
fluconazole were provided as generous gifts from Pfizer and Ranbaxy
Laboratories, respectively. The work presented in this paper has been
supported in part by grants to R. P. from the Department of Science and
Technology, Indo-Swiss (INT/SWISS/P-31/2009), Department of
Biotechnology (BT/PR9100/Med/29/ 03/2007, BT/PR9563/BRB/10/
567/2007, BT/PR11158/BRB/10/640/2008) and the Council of
Scientific and Industrial Research (CSIR) [38(1122)/06/EMR-II]. R.M.
thanks CSIR for the award of a senior research fellowship.
REFERENCES
Akins, R. A. (2005). An update on antifungal targets and mechanisms
of resistance in Candida albicans. Med Mycol 43, 285–318.
Chen, C. G., Yang, Y. L., Shih, H. I., Su, C. L. & Lo, H. J. (2004).
CaNdt80 is involved in drug resistance in Candida albicans by
regulating CDR1. Antimicrob Agents Chemother 48, 4505–4512.
Coste, A. T., Karababa, M., Ischer, F., Bille, J. & Sanglard, D. (2004).
TAC1, transcriptional activator of CDR genes, is a new transcription
factor involved in the regulation of Candida albicans ABC
transporters CDR1 and CDR2. Eukaryot Cell 3, 1639–1652.
Coste, A., Turner, V., Ischer, F., Morschha¨user, J., Forche, A.,
Selmecki, A., Berman, J., Bille, J. & Sanglard, D. (2006). A mutation
in Tac1p, a transcription factor regulating CDR1 and CDR2, is
coupled with loss of heterozygosity at chromosome 5 to mediate
antifungal resistance in Candida albicans. Genetics 172, 2139–2156.
De Micheli, M., Bille, J., Schuller, C. & Sanglard, D. (2002). A
common drug-responsive element mediates the upregulation of the
Candida albicans ABC transporters CDR1 and CDR2, two genes
involved in antifungal drug resistance. Mol Microbiol 43, 1197–1214.
Edwalds-Gilbert, G., Veraldi, K. L. & Milcarek, C. (1997). Alternative
poly(A) site selection in complex transcription units: means to an
end? Nucleic Acids Res 25, 2547–2561.
Fonzi, W. A. & Irwin, M. Y. (1993). Isogenic strain construction and
gene mapping in Candida albicans. Genetics 134, 717–728.
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M. &
Morschha¨user, J. (1998). Multiple molecular mechanisms contribute
to a stepwise development of fluconazole resistance in clinical
Candida albicans strains. Antimicrob Agents Chemother 42, 3065–
3072.
Franz, R., Ruhnke, M. & Morschha¨user, J. (1999). Molecular aspects
of fluconazole resistance development in Candida albicans. Mycoses
42, 453–458.
Garcia-Vivas, J., Lopez-Camarillo, C., Zuara-Liceaga, E., Orozco, E.
& Marchat, L. A. (2005). Entamoeba histolytica: cloning and expression
of the poly(A) polymerase EhPAP. Exp Parasitol 110, 226–232.
Gaur, N. A., Puri, N., Karnani, N., Mukhopadhyay, G., Goswami, S. K.
& Prasad, R. (2004). Identification of a negative regulatory element
which regulates basal transcription of a multidrug resistance gene
CDR1 of Candida albicans. FEMS Yeast Res 4, 389–399.
Gerads, M. & Ernst, J. F. (1998). Overlapping coding regions and
trancriptional units of two essential chromosomal genes (CCT8,
TRP1) in the fungal pathogen Candida albicans. Nucleic Acids Res 26,
5061–5066.
Higgins, C. F. (1991). Stability and degradation of mRNA. Curr Opin
Cell Biol 3, 1013–1018.
Holm, L. & Sander, C. (1995). DNA polymerase b belongs to ancient
nucleotidyltransferase superfamily. Trends Biochem Sci 20, 345–347.
Hsu, S. I., Cohen, D., Kirschner, L. S., Lothstein, L., Hartstein, M. &
Horwitz, S. B. (1990). Structural analysis of the mouse mdr1a (P-
glycoprotein) promoter reveals the basis for differential transcript
heterogeneity in multidrug-resistant J774.2 cells. Mol Cell Biol 10,
3596–3606.
Hull, C. M. & Johnson, A. D. (1999). Identification of a mating type-
like locus in the asexual pathogenic yeast Candida albicans. Science
285, 1271–1275.
Jiang, B., Xu, D., Allocco, J., Parish, C., Davison, J., Veillette, K.,
Sillaots, S., Hu, W., Rodriguez-Suarez, R. & other authors (2008).
PAP inhibitor with in vivo efficacy identified by Candida albicans
genetic profiling of natural products. Chem Biol 15, 363–374.
Karnani, N., Gaur, N. A., Jha, S., Puri, N., Krishnamurthy, S.,
Goswami, S. K., Mukhopadhyay, G. & Prasad, R. (2004). SRE1 and
SRE2 are two specific steroid-responsive modules of Candida drug
resistance gene 1 (CDR1) promoter. Yeast 21, 219–239.
Kusov, Y. Y., Shatirishvili, G., Dzagurov, G. & Gauss-Muller, V.
(2001). A new G-tailing method for the determination of the
poly(A) tail length applied to hepatitis A virus RNA. Nucleic Acids Res
29, E57.
Lopez-Camarillo, C., Luna-Arias, J. P., Marchat, L. A. & Orozco, E.
(2003). EhPgp5 mRNA stability is a regulatory event in the Entamoeba
histolytica multidrug resistance phenotype. J Biol Chem 278, 11273–
11280.
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White,
T. C., Sanglard, D. & Patterson, T. F. (1998). Distinct patterns of gene
expression associated with development of fluconazole resistance in
serial Candida albicans isolates from human immunodeficiency virus-
infected patients with oropharyngeal candidiasis. Antimicrob Agents
Chemother 42, 2932–2937.
Magee, B. B. & Magee, P. T. (2000). Induction of mating in Candida
albicans by construction of MTLa and MTLa strains. Science 289,
310–313.
Manoharlal, R., Gaur, N. A., Panwar, S. L., Morschha¨user, J. &
Prasad, R. (2008). Transcriptional activation and increased mRNA
stability contribute to overexpression of CDR1 in azole-resistant
Candida albicans. Antimicrob Agents Chemother 52, 1481–1492.
McCarthy, J. E. (1998). Post-transcriptional control of gene
expression in yeast. Microbiol Mol Biol Rev 62, 1492–1553.
Morschha¨user, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J.,
Homayouni, R. & Rogers, P. D. (2007). The transcription factor
Mrr1p controls expression of the MDR1 efflux pump and mediates
multidrug resistance in Candida albicans. PLoS Pathog 3, e164.
Murad, A. M., Lee, P. R., Broadbent, I. D., Barelle, C. J. & Brown, A. J.
(2000). CIp10, an efficient and convenient integrating vector for
Candida albicans. Yeast 16, 325–327.
Pesole, G. & Liuni, S. (1999). Internet resources for the functional
analysis of 59 and 39 untranslated regions of eukaryotic mRNAs.
Trends Genet 15, 378.
Pesole, G., Liuni, S., Grillo, G., Licciulli, F., Mignone, F., Gissi, C. &
Saccone, C. (2002). UTRdb and UTRsite: specialized databases of
sequences and functional elements of 59 and 39 untranslated regions
of eukaryotic mRNAs. Update. Nucleic Acids Res 30, 335–340.
Prasad, R., De, W. P., Goffeau, A. & Balzi, E. (1995). Molecular
cloning and characterization of a novel gene of Candida albicans,
Regulation of MDR in Candida albicans
http://mic.sgmjournals.org 325
CDR1, conferring multiple resistance to drugs and antifungals. Curr
Genet 27, 320–329.
Prokipcak, R. D., Raouf, A. & Lee, C. (1999). The AU-rich 39
untranslated region of human MDR1 mRNA is an inefficient mRNA
destabilizer. Biochem Biophys Res Commun 261, 627–634.
Puri, N., Krishnamurthy, S., Habib, S., Hasnain, S. E., Goswami, S. K.
& Prasad, R. (1999). CDR1, a multidrug resistance gene from Candida
albicans, contains multiple regulatory domains in its promoter and
the distal AP-1 element mediates its induction by miconazole. FEMS
Microbiol Lett 180, 213–219.
Reuss, O., Vik, A., Kolter, R. & Morschha¨user, J. (2004). The SAT1
flipper, an optimized tool for gene disruption in Candida albicans.
Gene 341, 119–127.
Rognon, B., Kozovska, Z., Coste, A. T., Pardini, G. & Sanglard, D.
(2006). Identification of promoter elements responsible for the
regulation of MDR1 from Candida albicans, a major facilitator
transporter involved in azole resistance. Microbiology 152, 3701–3722.
Ross, J. (1996). Control of messenger RNA stability in higher
eukaryotes. Trends Genet 12, 171–175.
Russell, J. E., Morales, J., Makeyev, A. V. & Liebhaber, S. A. (1998).
Sequence divergence in the 39 untranslated regions of human f- and
a-globin mRNAs mediates a difference in their stabilities and
contributes to efficient a- to -f gene development switching. Mol
Cell Biol 18, 2173–2183.
Sanglard, D. & Odds, F. C. (2002). Resistance of Candida species to
antifungal agents: molecular mechanisms and clinical consequences.
Lancet Infect Dis 2, 73–85.
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M. & Bille, J.
(1995). Mechanisms of resistance to azole antifungal agents in
Candida albicans isolates from AIDS patients involve specific
multidrug transporters. Antimicrob Agents Chemother 39, 2378–2386.
Sanglard, D., Ischer, F., Monod, M. & Bille, J. (1996). Susceptibilities
of Candida albicans multidrug transporter mutants to various
antifungal agents and other metabolic inhibitors. Antimicrob Agents
Chemother 40, 2300–2305.
Sanglard, D., Ischer, F., Monod, M. & Bille, J. (1997). Cloning of
Candida albicans genes conferring resistance to azole antifungal
agents: characterisation of CDR2, a new multidrug ABC transporter
gene. Microbiology 143, 405–416.
Sparks, K. A. & Dieckmann, C. L. (1998). Regulation of poly(A) site
choice of several yeast mRNAs. Nucleic Acids Res 26, 4676–4687.
Talibi, D. & Raymond, M. (1999). Isolation of a putative Candida
albicans transcriptional regulator involved in pleiotropic drug
resistance by functional complementation of a pdr1 pdr3 mutation
in Saccharomyces cerevisiae. J Bacteriol 181, 231–240.
Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment
through sequence weighting, position-specific gap penalties and
weight matrix choice. Nucleic Acids Res 22, 4673–4680.
Trzaska, D. & Dastych, J. (2005). Role of AURE sequences in the
regulation of mRNA stability. Postepy Biochem 51, 28–35.
Uhl, M. A. & Johnson, A. D. (2001). Development of Streptococcus
thermophilus lacZ as a reporter gene for Candida albicans.
Microbiology 147, 1189–1195.
White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and
MDR1 correlate with increases in azole resistance in Candida albicans
isolates from a patient infected with human immunodeficiency virus.
Antimicrob Agents Chemother 41, 1482–1487.
White, T. C., Pfaller, M. A., Rinaldi, M. G., Smith, J. & Redding, S. W.
(1997). Stable azole drug resistance associated with a substrain of
Candida albicans from an HIV-infected patient. Oral Dis 3 (suppl. 1),
S102–S109.
White, T. C., Marr, K. A. & Bowden, R. A. (1998). Clinical, cellular, and
molecular factors that contribute to antifungal drug resistance. Clin
Microbiol Rev 11, 382–402.
Wirsching, S., Michel, S., Kohler, G. & Morschha¨user, J. (2000).
Activation of the multiple drug resistance gene MDR1 in fluconazole-
resistant, clinical Candida albicans strains is caused by mutations in a
trans-regulatory factor. J Bacteriol 182, 400–404.
Yang, Y. L., Lin, Y. H., Tsao, M. Y., Chen, C. G., Shih, H. I., Fan, J. C.,
Wang, J. S. & Lo, H. J. (2006). Serum repressing efflux pump CDR1 in
Candida albicans. BMC Mol Biol 7, 22.
Zhao, J., Hyman, L. & Moore, C. (1999). Formation of mRNA 39 ends
in eukaryotes: mechanism, regulation, and interrelationships with
other steps in mRNA synthesis. Microbiol Mol Biol Rev 63, 405–445.
Znaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S.,
Drouin, S., Lemieux, S., De, D. X., Robert, F. & Raymond, M. (2008).
Genome-wide location analysis of Candida albicans Upc2p, a
regulator of sterol metabolism and azole drug resistance. Eukaryot
Cell 7, 836–847.
Zuker, M., Mathews, D. H. & Turner, D. H. (1999). Algorithms and
thermodynamics for RNA secondary structure prediction: a practical
guide. In RNA Biochemistry and Biotechnology, pp. 11–43. Edited by
J. Barciszewski & B. F. C. Clark. Boston, MA: Kluwer Academic
Publishers.
Edited by: J. F. Ernst
R. Manoharlal and others
326 Microbiology 156
